Literature DB >> 26850493

Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death.

Michael Asger Andersen1, Fie Juhl Vojdeman1, Mette Klarskov Andersen2, Peter de Nully Brown1, Christian Hartmann Geisler1, Ole Weis Bjerrum1, Carsten Utoft Niemann1.   

Abstract

Hypogammaglobulinemia is the most common immune deficiency in chronic lymphocytic leukemia (CLL). However, the prognostic significance in terms of morbidity and mortality remains controversial. We here evaluate the significance of hypogammaglobulinemia in terms of infections, treatment-free survival (TFS), and overall survival (OS). A total of 159 consecutive, newly diagnosed patients were included for analysis. Twenty-five patients (16%) had a moderate or severe infection within one year of diagnosis, but no associations were found between low immunoglobulin (Ig) levels and infections. In multivariate analysis, we found age (>65), high Binet stage, high β2-microglobulin, and Ig deficiency to be associated with shorter OS. Decreased levels of IgM, deletion of chromosome 17p and unmutated IGHV status had independent negative impact on TFS. Thus, patients with hypogammaglobulinemia did not suffer more from infections early in the disease course, and decreased Ig had independent negative prognostic impact in CLL.

Entities:  

Keywords:  Chronic lymphocytic leukemia; hypogammaglobulinemia; infection; overall survival; prognostic; treatment free survival

Mesh:

Substances:

Year:  2016        PMID: 26850493     DOI: 10.3109/10428194.2016.1142082

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

1.  Immune failure, infection and survival in chronic lymphocytic leukemia.

Authors:  Kyle R Crassini; O Giles Best; Stephen P Mulligan
Journal:  Haematologica       Date:  2018-07       Impact factor: 9.941

2.  and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study.

Authors:  Michael Asger Andersen; Casper Tabassum Eriksen; Christian Brieghel; Jorne Lionel Biccler; Caspar da Cunha-Bang; Marie Helleberg; Carsten Utoft Niemann
Journal:  Haematologica       Date:  2018-03-08       Impact factor: 9.941

3.  IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia.

Authors:  Ganchimeg Ishdorj; Erin Streu; Pascal Lambert; Harbhajan S Dhaliwal; Salaheddin M Mahmud; Spencer B Gibson; Versha Banerji; Aaron J Marshall; James B Johnston
Journal:  Blood Adv       Date:  2019-07-23

4.  Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients.

Authors:  Namrata Singh; Sarah L Mott; Grerk Sutamtewagul; Ashley McCarthy; Susan L Slager; James R Cerhan; Zuhair Ballas; Brian K Link
Journal:  EJHaem       Date:  2020-09-01

5.  Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections.

Authors:  Hartmut Link; Markus Kerkmann; Laura Holtmann
Journal:  Support Care Cancer       Date:  2022-03-07       Impact factor: 3.359

6.  Secondary Immunodeficiency Frequency in Patients with Chronic Lymphocytic Leukemia: The Relationship with Stage and Treatment.

Authors:  Osman Yokus; Konul Jafarli; Fettah Sametoglu; Hasan Goze; Istemi Serin
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2022-01-01

7.  Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies.

Authors:  P Kralickova; J Kuhnova; O Soucek; P Vodarek; P Zak; M Simkovic; M Motyckova; L Smolej; E Mala; C Andrys; J Krejsek; V Thon
Journal:  J Immunol Res       Date:  2017-12-17       Impact factor: 4.818

8.  Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients.

Authors:  Jasmine Chauzeix; Marie-Pierre Laforêt; Mélanie Deveza; Liam Crowther; Elodie Marcellaud; Paco Derouault; Anne-Sophie Lia; François Boyer; Nicolas Bargues; Guillaume Olombel; Arnaud Jaccard; Jean Feuillard; Nathalie Gachard; David Rizzo
Journal:  Cancer Med       Date:  2018-05-09       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.